Trial Profile
An Open-label, Single Administration Study to Characterize the Systemic Pharmacokinetics and Local Extent and Duration of Exposure of Triamcinolone Acetonide From FX006 in Patients With Osteoarthritis of the Knee
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Jan 2024
Price :
$35
*
At a glance
- Drugs Triamcinolone (Primary)
- Indications Osteoarthritis
- Focus Pharmacokinetics
- Sponsors Flexion Therapeutics; Pacira BioSciences
- 04 May 2017 According to a Flexion Therapeutics media release, data from this trial has been presented at the Osteoarthritis Research Society International (OARSI) 2017 World Congress.
- 28 Apr 2017 According to a Flexion Therapeutics media release data from this trial will be presented at the Osteoarthritis Research Society International (OARSI) 2017 World Congress.
- 23 Jan 2017 Status changed from active, no longer recruiting to completed.